This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Investors Heavily Search Procter & Gamble Company (The) (PG): Here is What You Need to Know
by Zacks Equity Research
P&G (PG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Clorox (CLX) Benefits From Strategic and Pricing Efforts
by Zacks Equity Research
Clorox (CLX) benefits from pricing actions and cost-saving initiatives. The company also boasts a solid innovation pipeline.
Is It Worth Investing in P&G (PG) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), P&G (PG) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Procter & Gamble (PG) Stock Moves -0.12%: What You Should Know
by Zacks Equity Research
In the most recent trading session, Procter & Gamble (PG) closed at $161.66, indicating a -0.12% shift from the previous trading day.
Should You Invest in the iShares U.S. Consumer Staples ETF (IYK)?
by Zacks Equity Research
Sector ETF report for IYK
Should You Invest in the Vanguard Consumer Staples ETF (VDC)?
by Zacks Equity Research
Sector ETF report for VDC
Procter & Gamble (PG) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the latest trading session, Procter & Gamble (PG) closed at $161.21, marking a -0.11% move from the previous day.
Procter & Gamble Company (The) (PG) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
P&G (PG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should You Invest in the Fidelity MSCI Consumer Staples Index ETF (FSTA)?
by Zacks Equity Research
Sector ETF report for FSTA
Procter & Gamble (PG) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Procter & Gamble (PG) closed at $161.93, marking a +0.24% move from the previous day.
Why This 1 Consumer Staples Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Procter & Gamble (PG) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the most recent trading session, Procter & Gamble (PG) closed at $161.55, indicating a +0.75% shift from the previous trading day.
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Is P&G (PG) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for P&G (PG) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Why the Market Dipped But Procter & Gamble (PG) Gained Today
by Zacks Equity Research
Procter & Gamble (PG) closed at $159.56 in the latest trading session, marking a +0.45% move from the prior day.
The Zacks Analyst Blog Highlights Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic
by Zacks Equity Research
Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic are part of the Zacks top Analyst Blog.
Procter & Gamble Company (The) (PG) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
P&G (PG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Top Analyst Reports for Eli Lilly, Procter & Gamble & Morgan Stanley
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), The Procter & Gamble Company (PG) and Morgan Stanley (MS).
Procter & Gamble (PG) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
The latest trading day saw Procter & Gamble (PG) settling at $160.22, representing a -0.5% change from its previous close.
Should You Invest in the Consumer Staples Select Sector SPDR ETF (XLP)?
by Zacks Equity Research
Sector ETF report for XLP
3 Companies Enjoying Meaningful Margin Expansion
by Derek Lewis
A favorable operating environment has led to increased profitability for many companies, causing many to see shares jump post-earnings throughout the 2023 Q4 cycle so far.
Company News for Jan 24, 2024
by Zacks Equity Research
Companies in The News Are: CBRE, VZ, PG, PEP
3 Hot Stocks to Buy Following Guidance Lifts
by Derek Lewis
Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture. Unsurprisingly, all three of these stocks popped following the lifts.
Mixed Q4 Earnings Report
by Zacks Equity Research
Mixed Q4 Earnings Report
Procter & Gamble (PG) Beats Q2 Earnings Estimates, Ups EPS View
by Zacks Equity Research
Procter & Gamble's (PG) Q2 results reflect robust pricing, along with growth across all segments. All its business segments have seen growth in organic sales.